Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-01-2019 | Original Article – Cancer Research

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines

Authors: Simona Camero, Simona Ceccarelli, Francesca De Felice, Francesco Marampon, Olga Mannarino, Lucrezia Camicia, Enrica Vescarelli, Paola Pontecorvi, Barry Pizer, Rajeev Shukla, Amalia Schiavetti, Maria Giovanna Mollace, Antonio Pizzuti, Vincenzo Tombolini, Cinzia Marchese, Francesca Megiorni, Carlo Dominici

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2019

Abstract

Purpose

PARP inhibitors (PARPi) are used in a wide range of human solid tumours but a limited evidence is reported in rhabdomyosarcoma (RMS), the most frequent childhood soft-tissue sarcoma. The cellular and molecular effects of Olaparib, a specific PARP1/2 inhibitor, and AZD2461, a newly synthesized PARP1/2/3 inhibitor, were assessed in alveolar and embryonal RMS cells both as single-agent and in combination with ionizing radiation (IR).

Methods

Cell viability was monitored by trypan blue exclusion dye assays. Cell cycle progression and apoptosis were measured by flow cytometry, and alterations of specific molecular markers were investigated by, Real Time PCR, Western blotting and immunofluorescence experiments. Irradiations were carried out at a dose rate of 2 Gy (190 UM/min) or 4 Gy (380 UM/min). Radiosensitivity was assessed by using clonogenic assays.

Results

Olaparib and AZD2461 dose-dependently reduced growth of both RH30 and RD cells by arresting growth at G2/M phase and by modulating the expression, activation and subcellular localization of specific cell cycle regulators. Downregulation of phospho-AKT levels and accumulation of γH2AX, a specific marker of DNA damage, were significantly and persistently induced by Olaparib and AZD2461 exposure, this leading to apoptosis-related cell death. Both PARPi significantly enhanced the effects of IR by accumulating DNA damage, increasing G2 arrest and drastically reducing the clonogenic capacity of RMS-cotreated cells.

Conclusions

This study suggests that the combined exposure to PARPi and IR might display a role in the treatment of RMS tumours compared with single-agent exposure, since stronger cytotoxic effects are induced, and compensatory survival mechanisms are prevented.

Available only for authorised users

Anderson J, Gordon A, Pritchard-Jones K, Shipley J (1999) Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosom Cancer 26:275–285CrossRefPubMed

Arndt CAS, Stoner JA, Hawkins DS et al (2009) Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol 27:5182–5188. https://doi.org/10.1200/JCO.2009.22.3768 CrossRefPubMedPubMedCentral

Bai P (2015) Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell 58:947–958CrossRefPubMed

Bang Y-J, Im S-A, Lee K-W et al (2013) Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study. J Clin Oncol 31

Boehler C, Gauthier LR, Mortusewicz O et al (2011) Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci 108:2783–2788. https://doi.org/10.1073/pnas.1016574108 CrossRefPubMedPubMedCentral

Bonner WM, Redon CE, Dickey JS et al (2008) GammaH2AX and cancer. Nat Rev Cancer 8:957–967. https://doi.org/10.1038/nrc2523 CrossRefPubMedPubMedCentral

Bridges KA, Toniatti C, Buser CA et al (2014) Niraparib (MK-4827), a novel poly(ADP-ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget 5:5076–5086. https://doi.org/10.18632/oncotarget.2083 CrossRefPubMedPubMedCentral

Brown JS, O’Carrigan B, Jackson SP, Yap TA (2017) Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov 7:20–37CrossRefPubMed

Coffin CM (1997) The new international rhabdomyosarcoma classification, its progenitors, and considerations beyond morphology. Adv Anat Pathol 4:1–16. https://doi.org/10.1097/00125480-199701000-00001 CrossRef

Costanzo V (2011) Brca2, Rad51 and Mre11: Performing balancing acts on replication forks. DNA Repair 10:1060–1065. https://doi.org/10.1016/j.dnarep.2011.07.009 CrossRefPubMed

D’Arcangelo M, Drew Y, Plummer R (2016) The role of PARP in DNA repair and its therapeutic exploitation. In: Kelley MR, Fishel ML (eds) DNA repair in cancer therapy: molecular targets and clinical applications, 2nd edn. Academic Press of Elsevier, London, pp 115–134CrossRef

Davis AJ, Chen DJ (2013) DNA double strand break repair via non-homologous end-joining. Transl Cancer Res 2:130–143PubMed

De Vos M, Schreiber V, Dantzer F (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 84:137–146CrossRefPubMed

Dedes KJ, Wetterskog D, Mendes-Pereira AM et al (2010) PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. https://doi.org/10.1126/scitranslmed.3001538 CrossRefPubMed

Duangmano S, Sae-Lim P, Suksamrarn A et al (2012) Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest. J Oncol. https://doi.org/10.1155/2012/601682 CrossRefPubMedPubMedCentral

Dungey FA, Löser DA, Chalmers AJ (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72:1188–1197. https://doi.org/10.1016/j.ijrobp.2008.07.031 CrossRefPubMed

Ferrari A, Dileo P, Casanova M et al (2003) Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. Cancer 98:571–580. https://doi.org/10.1002/cncr.11550 CrossRefPubMed

Flygare J, Fält S, Ottervald J et al (2001) Effects of HsRad51 overexpression on cell proliferation, cell cycle progression, and apoptosis. Exp Cell Res 268:61–69. https://doi.org/10.1006/excr.2001.5265 CrossRefPubMed

Goldstein M, Meller I, Issakov J, Orr-Urtreger A (2006) Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. NEO 8:332–343. https://doi.org/10.1593/neo.05829 CrossRef

Goulooze SC, Cohen AF, Rissmann R (2016) Olaparib. Br J Clin Pharmacol 81:171–173. https://doi.org/10.1111/bcp.12761 CrossRefPubMed

He J, Kang X, Yin Y et al (2015) PTEN regulates DNA replication progression and stalled fork recovery. Nat Commun 6:. https://doi.org/10.1038/ncomms8620

Helleday T, Lo J, van Gent DC, Engelward BP (2007) DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair 6:923–935. https://doi.org/10.1016/j.dnarep.2007.02.006 CrossRefPubMed

Henning W, Stürzbecher HW (2003) Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 193:91–109CrossRefPubMed

Jaspers JE, Kersbergen A, Boon U et al (2013) Loss of 53BP1 causes PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors. Cancer Discov 3:68–81. https://doi.org/10.1158/2159-8290.CD-12-0049 CrossRefPubMed

Jin P, Gu Y, Morgan DO (1996) Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 134:963–970. https://doi.org/10.1083/jcb.134.4.963 CrossRefPubMed

Jorgensen TJ (2009) Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 8:665–670CrossRefPubMed

Kelley MR, Logsdon D, Fishel ML (2014) Targeting DNA repair pathways for cancer treatment: what’s new? Futur Oncol 10:1215–1237. https://doi.org/10.2217/fon.14.60 CrossRef

Kilic-Eren M, Boylu T, Tabor V (2013) Targeting PI3K/Akt represses hypoxia inducible factor-1α activation and sensitizes rhabdomyosarcoma and Ewing’s sarcoma cells for apoptosis. Cancer Cell Int. https://doi.org/10.1186/1475-2867-13-36 CrossRefPubMedPubMedCentral

Kim G, Ison G, McKee AE et al (2015) FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 21:4257–4261. https://doi.org/10.1158/1078-0432.CCR-15-0887 CrossRefPubMed

Klein HL (2008) The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair 7:686–693CrossRefPubMedPubMedCentral

Kuo LJ, Yang L-X (2008) Gamma-H2AX—a novel biomarker for DNA double-strand breaks. In Vivo 22:305–309PubMed

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(− Delta Delta C(T)) method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262 CrossRefPubMed

Löbrich M, Shibata A, Beucher A et al (2010) gammaH2AX foci analysis for monitoring DNA double-strand break repair. Cell Cycle 9:662–669. https://doi.org/10.4161/cc.9.4.10764 CrossRefPubMed

Lord CJ, Ashworth A (2017) PARP inhibitors: synthetic lethality in the clinic. Science 355:1152–1158. https://doi.org/10.1126/science.aam7344 CrossRefPubMedPubMedCentral

Ma J, Weng L, Wang Z et al (2018) MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis. Exp Cell Res 366:103–113. https://doi.org/10.1016/j.yexcr.2018.02.037 CrossRefPubMed

Mangoni M, Sottili M, Salvatore G et al (2018) Enhancement of soft tissue sarcoma cell radiosensitivity by poly(ADP-ribose) polymerase-1 inhibitors. Radiat Res. https://doi.org/10.1667/RR15035.1 CrossRefPubMed

Marshall AD, Grosveld GC (2012) Alveolar rhabdomyosarcoma—the molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. Skelet Muscle 2:25. https://doi.org/10.1186/2044-5040-2-25 CrossRefPubMedPubMedCentral

Martin SA, Lord CJ, Ashworth A (2008) DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 18:. https://doi.org/10.1016/j.gde.2008.01.016

Martinelli S, McDowell HP, Vigne SD et al (2009) RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosom Cancer 48:975–982. https://doi.org/10.1002/gcc.20702 CrossRefPubMed

McDowell HP (2003) Update on childhood rhabdomyosarcoma. Arch Dis Child 88:354–357. https://doi.org/10.1136/adc.88.4.354 CrossRefPubMedPubMedCentral

McEllin B, Camacho CV, Mukherjee B et al (2010) PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly[ADP-ribose] polymerase inhibitors. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-09-4295 CrossRefPubMedPubMedCentral

Megiorni F, Cialfi S, McDowell HP et al (2014) Deep sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members. BMC Cancer 14:880. https://doi.org/10.1186/1471-2407-14-880 CrossRefPubMedPubMedCentral

Megiorni F, Camero S, Ceccarelli S et al (2016) DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation. Oncotarget 7:79342–79356. https://doi.org/10.18632/oncotarget.12688 CrossRefPubMedPubMedCentral

Mendes-Pereira AM, Martin SA, Brough R et al (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. https://doi.org/10.1002/emmm.200900041 CrossRefPubMedPubMedCentral

Merlino G, Helman LJ (1999) Rhabdomyosarcoma—working out the pathways. Oncogene 18:5340–5348. https://doi.org/10.1038/sj.onc.1203038 CrossRefPubMed

Mueller S, Bhargava S, Molinaro AM et al (2013) Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res 33:755–762PubMedPubMedCentral

Murai SY, Huang BB, Das A et al (2012) Pommier trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-12-2753 CrossRefPubMedPubMedCentral

O’Connor LO, Rulten SL, Cranston AN et al (2016) The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models. Cancer Res 76:6084–6094. https://doi.org/10.1158/0008-5472.CAN-15-3240 CrossRefPubMed

O’Neill JP, Bilsky MH, Kraus D (2013) Head and neck sarcomas. Epidemiology, pathology, and management. Neurosurg Clin N Am 24:67–78CrossRefPubMed

Ognjanovic S, Linabery AM, Charbonneau B, Ross JA (2009) Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer 115:4218–4226. https://doi.org/10.1002/cncr.24465 CrossRefPubMed

Parham DM, Barr FG (2013) Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol 20:387–397. https://doi.org/10.1097/PAP.0b013e3182a92d0d CrossRefPubMedPubMedCentral

Pawlik TM, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59:928–942CrossRefPubMed

Polo SE, Jackson SP (2011) Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. https://doi.org/10.1101/gad.2021311 CrossRefPubMedPubMedCentral

Robbins KM, Stabley DL, Holbrook J et al (2016) Paternal uniparental disomy with segmental loss of heterozygosity of chromosome 11 are hallmark characteristics of syndromic and sporadic embryonal rhabdomyosarcoma. Am J Med Genet Part A 170:3197–3206. https://doi.org/10.1002/ajmg.a.37949 CrossRefPubMed

Sorensen PHB, Lynch JC, Qualman SJ et al (2002) PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol 20:2672–2679. https://doi.org/10.1200/JCO.2002.03.137 CrossRefPubMed

Vaidyanathan A, Sawers L, Gannon AL et al (2016) ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer 115:431–441. https://doi.org/10.1038/bjc.2016.203 CrossRefPubMedPubMedCentral

Venere M, Hamerlik P, Wu Q et al (2014) Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ 21:258–269. https://doi.org/10.1038/cdd.2013.136 CrossRefPubMed

Verhagen CVM, De Haan R, Hageman F et al (2015) Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. In: Radiotherapy and oncology, pp 358–365

Vignard J, Mirey G, Salles B (2013) Ionizing-radiation induced DNA double-strand breaks: a direct and indirect lighting up. Radiother Oncol 108:362–369CrossRefPubMed

Wang Y, Chen L, Wu Z et al (2016) miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL. BMC Cancer. https://doi.org/10.1186/s12885-016-2862-4 CrossRefPubMedPubMedCentral

Wiltshire TD, Lovejoy CA, Wang T et al (2010) Sensitivity to poly[ADP-ribose] polymerase [PARP] inhibition identifies ubiquitin-specific peptidase 11 [USP11] as a regulator of DNA double-strand break repair. J Biol Chem. https://doi.org/10.1074/jbc.M110.104745 CrossRefPubMedPubMedCentral

Wolden SL, Lyden ER, Arndt CA et al (2015) Local control for intermediate-risk rhabdomyosarcoma: results from D9803 according to histology, group, site, and size: a report from the children’s oncology group. Int J Radiat Oncol Biol Phys 93:1071–1076. https://doi.org/10.1016/j.ijrobp.2015.08.040 CrossRefPubMedPubMedCentral

Yélamos J, Schreiber V, Dantzer F (2008) Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 14:169–178. https://doi.org/10.1016/j.molmed.2008.02.003 CrossRefPubMed

Yoo S, McKee BD (2004) Overexpression of Drosophila Rad51 protein (DmRad51) disrupts cell cycle progression and leads to apoptosis. Chromosoma 113:92–101. https://doi.org/10.1007/s00412-004-0300-x CrossRefPubMed

Zhang Y, Zheng L, Lin S et al (2017) MiR-124 enhances cell radiosensitivity by targeting PDCD6 in nasopharyngeal carcinoma. Int J Clin Exp Pathol 10:11461–11470PubMedPubMedCentral

Zhang G, Chen L, Khan AA et al (2018) miRNA-124-3p/neuropilin-1(NRP-1) axis plays an important role in mediating glioblastoma growth and angiogenesis. Int J Cancer 143:635–644. https://doi.org/10.1002/ijc.31329 CrossRefPubMed

Zhu B, Zhang M, Williams EM et al (2016) TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle. Oncogene 35:4212–4224. https://doi.org/10.1038/onc.2015.486 CrossRefPubMed

Title: PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines
Authors: Simona Camero
Simona Ceccarelli
Francesca De Felice
Francesco Marampon
Olga Mannarino
Lucrezia Camicia
Enrica Vescarelli
Paola Pontecorvi
Barry Pizer
Rajeev Shukla
Amalia Schiavetti
Maria Giovanna Mollace
Antonio Pizzuti
Vincenzo Tombolini
Cinzia Marchese
Francesca Megiorni
Carlo Dominici
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2774-6

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer

Microbiota in cancer development and treatment

Surgical staging in endometrial cancer

DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma

Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma

Multiple functions of HuR in urinary tumors

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page